 CAMBRIDGE, Mass., March 09, 2021 GLOBE NEWSWIRE -- Jounce Therapeutics, Inc. Nasdaq: JNCE, a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it has priced an underwritten public offering of 5,000,000 shares of common stock at a public offering price of 11.25 per share, which would result in gross proceeds of approximately 56.25 million, before underwriting discounts and commissions. 